Daxor Corporation Announces Transition To Securities Exchange Act of 1934 Reporting Company, Reaffirming Focus on Core Blood Volume Analysis and Diagnostic Business

Rhea-AI Summary

Daxor (NASDAQ: DXR) announced it intends to change its primary reporting framework from the Investment Company Act to the Securities Exchange Act, reflecting its shift to an operating medical diagnostics business focused on Blood Volume Analysis (BVA). The company cited customer growth, revenue increases, and FDA clearance of its next-generation analyzer. Daxor expects to complete regulatory steps by the end of Q2, subject to required filings and approvals, and said Exchange Act reporting will provide standardized GAAP disclosures and improved investor comparability.

Positive

• FDA clearance of next-generation blood volume analyzer
• Transition to Exchange Act reporting for GAAP comparability
• Reported customer and revenue growth for core BVA business

Negative

• Transition is subject to regulatory filings and approvals
• Completion targeted by end of Q2 but not guaranteed

News Market Reaction

-0.41%

1 alert

-0.41% News Effect

On the day this news was published, DXR declined 0.41%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Reality Check

Price: $12.20 Vol: Volume 3001 vs 20-day ave...

low vol

$12.20 Last Close

Volume Volume 3001 vs 20-day average 6506 ahead of the reporting change news. low

Technical Price $12.25 is trading above the 200-day MA at $11.03.

Peers on Argus

DXR slipped 0.77% while close peers were mixed: AKYA -8.51%, ZJYL -3.9%, ZTEK -2...

1 Up

DXR slipped 0.77% while close peers were mixed: AKYA -8.51%, ZJYL -3.9%, ZTEK -2.09%, PDEX +0.13%, MLSS +4.54%. Momentum scanners only flagged MBOT at +13.04%, suggesting today’s move was stock-specific rather than a broad sector rotation.

Historical Context

5 past events · Latest: Jan 23 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 23	Capital raise offering	Negative	-8.1%	Registered direct equity offering raising about $9M for corporate purposes.
Nov 25	Commercial expansion	Positive	-1.9%	Three new facility adoptions and deployment of next-gen BVA analyzer.
Oct 21	Investor conference	Neutral	+2.0%	CEO meetings with institutional investors at Maxim Growth Summit.
Oct 15	Product showcase	Positive	-1.0%	Showcasing next‑generation BVA system at MedAxiom cardiovascular conference.
Sep 30	Clinical data & launch	Positive	+6.2%	Launch of FDA‑cleared BVA analyzer with pivotal clinical data at HFSA.

Pattern Detected

Financing news and strong clinical data have generally aligned with price moves, while some positive commercial and marketing updates have seen muted or negative reactions.

Recent Company History

Over the last six months, Daxor’s news flow has mixed capital raises, commercial wins, and clinical validation. A $9M registered direct offering on Jan 23, 2026 coincided with an -8.13% move, while unveiling an FDA-cleared next-generation BVA analyzer with >95% accuracy on Sep 30, 2025 saw shares gain 6.21%. Commercial expansion and conference appearances in late 2025 produced smaller, sometimes negative, reactions. Today’s transition toward Exchange Act reporting fits the ongoing shift from investment-company status toward an operating diagnostics profile.

Market Pulse Summary

This announcement highlights Daxor’s intention to pivot its primary reporting framework to the Secur...

Analysis

This announcement highlights Daxor’s intention to pivot its primary reporting framework to the Securities Exchange Act of 1934, reinforcing its identity as an operating medical diagnostics company rather than an investment company. The focus remains on its FDA‑cleared Blood Volume Analysis technology and standardized GAAP disclosures comparable to other medtech peers. Investors may track completion of regulatory steps by the end of the second quarter and weigh this shift alongside recent capital raises and ongoing commercialization milestones.

Key Terms

investment company act of 1940, exchange act, fda-cleared, gaap

4 terms

investment company act of 1940 regulatory

"transition its primary regulatory reporting framework from the Investment Company Act of 1940"

A U.S. federal law that sets the rulebook for pooled investment vehicles such as mutual funds, exchange-traded funds and similar money managers, requiring them to register with regulators, disclose holdings and fees, limit conflicts of interest, and follow governance standards. It matters to investors because these protections and transparency rules act like a referee and scoreboard, helping people compare funds, trust that managers follow fair practices, and spot hidden costs or risks.

exchange act regulatory

"represented under the Exchange Act framework, aligning regulatory status"

A federal law that sets rules for trading securities on public exchanges, requiring companies and market participants to register, disclose regular financial information, and follow standards that promote honest, orderly markets. For investors, it matters because it creates transparency and legal protections—like stopping insider trading and ensuring timely company disclosures—so you can evaluate risks and rely on consistent rules much as players rely on a referee to keep a game fair.

fda-cleared medical

"This is the only FDA-cleared diagnostic blood test providing objective"

FDA-cleared means a medical product—typically a device or diagnostic—has passed a U.S. regulator’s review showing it is substantially similar to an existing approved product and is safe and effective for its intended use. For investors, clearance acts like an official safety stamp that lowers regulatory risk and can speed market access, comparable to getting a trusted roadworthy certificate before selling cars, which can make sales and adoption happen faster.

gaap financial

"provide investors with standardized GAAP metrics and benchmarks"

GAAP, or Generally Accepted Accounting Principles, are a set of standardized rules and guidelines that companies follow when preparing their financial statements. They ensure consistency, transparency, and comparability across different companies, making it easier for investors to understand and compare financial information accurately. This helps investors make informed decisions based on trustworthy and uniform financial reports.

AI-generated analysis. Not financial advice.

Oak Ridge, TN, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announced its intention to transition its primary regulatory reporting framework from the Investment Company Act of 1940 (the Investment Company Act) to the Securities Exchange Act of 1934 (the “Exchange Act”), subject to its completion of required regulatory filings and approvals. This transition reflects the sustained rapid scaling and strategic maturation of the Company’s core diagnostic technology operating business.

The Company’s principal focus remains the development and commercialization of its market-leading Blood Volume Analysis (BVA) technology. This is the only FDA-cleared diagnostic blood test providing objective, patient-specific quantification of a patient’s total blood volume status and composition.

Key Highlights of the Transition

• Reaffirmed Focus on Operations: This transition validates the success of management’s strategy to prioritize and rapidly grow the core BVA technology division. This growth has been marked by significant developmental milestones, including revenue increases, new hospital system and medical practice customer acquisitions, and recent FDA-clearance of its next generation blood volume analyzer
• Alignment of Financial Profile: Operational growth has evolved to a point where the Company’s financial profile is now more accurately and appropriately represented under the Exchange Act framework, aligning regulatory status with the Company’s primary identity as an innovative medical device and diagnostic technology firm
• Enhanced Investor Clarity: Reporting under the Exchange Act will simplify financial disclosures and provide investors with standardized GAAP metrics and benchmarks in line with, and directly comparable to other publicly traded medical diagnostic companies. This alignment is expected to improve transparency and garner deeper institutional interest while expanding analyst coverage
  
  

"The strategic decision to transition back to Exchange Act reporting is a financial validation of our focused growth strategy," said Robert Michel, Daxor’s Chief Financial Officer. "Daxor has achieved the scale necessary to align our regulatory and operational frameworks with our identity as a high-growth medical diagnostic company, enhancing transparency and comparability for our investors."

Next Steps

The Company anticipates completing the necessary regulatory steps to fully effectuate the change in reporting status by the end of the second quarter, subject to completion of required regulatory filings and approvals.

About Daxor Corporation

Daxor Corporation (NASDAQ: DXR) is tackling healthcare's "multi-billion-dollar silent crisis", the inability to precisely measure blood volume. This often results in suboptimal care, prolonged hospital stays, and increased readmissions for many high-cost medical conditions like heart failure and those requiring ICU care. With 50 years of experience and innovation, Daxor is proud to manufacture and distribute its patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic which offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. This empowers clinicians to make individualized treatment decisions that significantly improve patient outcomes and deliver substantial efficiencies in value-based healthcare. Daxor is ISO certified and operates a U.S.-based, 20,000-square-foot state-of-the-art manufacturing facility, positioning the company for accelerated market expansion.

For more information, please visit our website at Daxor.com.

Sign up to receive news on Daxor’s innovative technology HERE.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Investors in registered investment companies benefit from legal protections imposed for their benefit under the Investment Company Act, and those legal protections will no longer apply if we receive the requested order. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
Bret Shapiro
COO – Head of Capital Markets
COREIR
(516) 222 2560
brets@coreir.com|www.coreir.com

FAQ

What does Daxor (DXR) transitioning to Exchange Act reporting mean for investors?

It means investors will see standardized GAAP disclosures and peer comparability. According to the company, Exchange Act reporting aims to simplify financials, provide standardized metrics, and improve transparency to attract deeper institutional interest and expanded analyst coverage.

Has Daxor (DXR) received FDA clearance for any new products?

Yes — Daxor announced FDA clearance of its next-generation blood volume analyzer. According to the company, this clearance supports commercialization of its BVA diagnostic test and validates its focus on scalable diagnostic operations.

When does Daxor (DXR) expect to complete the reporting transition to the Exchange Act?

Daxor expects to complete the reporting change by the end of the second quarter, subject to approvals. According to the company, completion depends on required regulatory filings and approvals and timing remains conditional.

How will Exchange Act reporting affect Daxor's financial disclosures (DXR)?

Exchange Act reporting will provide standardized GAAP metrics and benchmarks for comparability. According to the company, investors should see simpler disclosures aligned with other public diagnostic companies, which may improve transparency and institutional interest.

Does the DXR announcement describe operational growth or new customers?

Yes — the company cited revenue increases and new hospital and medical practice customers for its BVA technology. According to the company, these customer additions and revenue trends reflect scaling of its core diagnostic operating business.